Comparative genomics and the development of antimalarial and antiparasitic therapeutics

Emilio F. Merino, Steven A. Sullivan, Jane Carlton

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

We are in the midst of a transformation in the study of eukaryotic parasites, a transformation sparked by the vast amounts of genome sequence data becoming available for many of the species in this diverse group. In this review, we summarize the current state of parasite genomics, provide details concerning the available drug andvaccine therapies for the diseases caused by these parasites, and describe the roles comparative genomics is playing in the design of new drugs and vaccines against them. These roles include the identification of various metabolic pathways or proteins that might serve as therapeutic targets by virtue of their presence in the parasite but absence in humans; elucidation of the causes of drug resistance and antibiotic sensitivity; identification of genes expressed in a stage-specific fashion; and detection of potential antigens for vaccine development. The future is bright for comparative genomic analysis of parasites, and the development of several public-private partnerships that foster collaborations among scientists in academia, big pharmaceutical companies, and the public sector provide new hope for the development of the next generation of antiparasitic therapeutics.

Original languageEnglish (US)
Title of host publicationComparative Genomics
Subtitle of host publicationBasic and Applied Research
PublisherCRC Press
Pages193-218
Number of pages26
ISBN (Electronic)9781420008876
ISBN (Print)9780849392160
DOIs
StatePublished - Jan 1 2007

Fingerprint

Antiparasitic Agents
Antimalarials
Genomics
Parasites
Vaccines
Genes
Public-Private Sector Partnerships
Pharmaceutical Preparations
Drug therapy
Therapeutics
Public Sector
Drug Design
Metabolic Networks and Pathways
Drug Resistance
Genome
Anti-Bacterial Agents
Antigens
Drug Therapy
Industry
Proteins

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Merino, E. F., Sullivan, S. A., & Carlton, J. (2007). Comparative genomics and the development of antimalarial and antiparasitic therapeutics. In Comparative Genomics: Basic and Applied Research (pp. 193-218). CRC Press. https://doi.org/10.1201/9781420008876

Comparative genomics and the development of antimalarial and antiparasitic therapeutics. / Merino, Emilio F.; Sullivan, Steven A.; Carlton, Jane.

Comparative Genomics: Basic and Applied Research. CRC Press, 2007. p. 193-218.

Research output: Chapter in Book/Report/Conference proceedingChapter

Merino, EF, Sullivan, SA & Carlton, J 2007, Comparative genomics and the development of antimalarial and antiparasitic therapeutics. in Comparative Genomics: Basic and Applied Research. CRC Press, pp. 193-218. https://doi.org/10.1201/9781420008876
Merino EF, Sullivan SA, Carlton J. Comparative genomics and the development of antimalarial and antiparasitic therapeutics. In Comparative Genomics: Basic and Applied Research. CRC Press. 2007. p. 193-218 https://doi.org/10.1201/9781420008876
Merino, Emilio F. ; Sullivan, Steven A. ; Carlton, Jane. / Comparative genomics and the development of antimalarial and antiparasitic therapeutics. Comparative Genomics: Basic and Applied Research. CRC Press, 2007. pp. 193-218
@inbook{934448175a7641268cf903232985fad2,
title = "Comparative genomics and the development of antimalarial and antiparasitic therapeutics",
abstract = "We are in the midst of a transformation in the study of eukaryotic parasites, a transformation sparked by the vast amounts of genome sequence data becoming available for many of the species in this diverse group. In this review, we summarize the current state of parasite genomics, provide details concerning the available drug andvaccine therapies for the diseases caused by these parasites, and describe the roles comparative genomics is playing in the design of new drugs and vaccines against them. These roles include the identification of various metabolic pathways or proteins that might serve as therapeutic targets by virtue of their presence in the parasite but absence in humans; elucidation of the causes of drug resistance and antibiotic sensitivity; identification of genes expressed in a stage-specific fashion; and detection of potential antigens for vaccine development. The future is bright for comparative genomic analysis of parasites, and the development of several public-private partnerships that foster collaborations among scientists in academia, big pharmaceutical companies, and the public sector provide new hope for the development of the next generation of antiparasitic therapeutics.",
author = "Merino, {Emilio F.} and Sullivan, {Steven A.} and Jane Carlton",
year = "2007",
month = "1",
day = "1",
doi = "10.1201/9781420008876",
language = "English (US)",
isbn = "9780849392160",
pages = "193--218",
booktitle = "Comparative Genomics",
publisher = "CRC Press",

}

TY - CHAP

T1 - Comparative genomics and the development of antimalarial and antiparasitic therapeutics

AU - Merino, Emilio F.

AU - Sullivan, Steven A.

AU - Carlton, Jane

PY - 2007/1/1

Y1 - 2007/1/1

N2 - We are in the midst of a transformation in the study of eukaryotic parasites, a transformation sparked by the vast amounts of genome sequence data becoming available for many of the species in this diverse group. In this review, we summarize the current state of parasite genomics, provide details concerning the available drug andvaccine therapies for the diseases caused by these parasites, and describe the roles comparative genomics is playing in the design of new drugs and vaccines against them. These roles include the identification of various metabolic pathways or proteins that might serve as therapeutic targets by virtue of their presence in the parasite but absence in humans; elucidation of the causes of drug resistance and antibiotic sensitivity; identification of genes expressed in a stage-specific fashion; and detection of potential antigens for vaccine development. The future is bright for comparative genomic analysis of parasites, and the development of several public-private partnerships that foster collaborations among scientists in academia, big pharmaceutical companies, and the public sector provide new hope for the development of the next generation of antiparasitic therapeutics.

AB - We are in the midst of a transformation in the study of eukaryotic parasites, a transformation sparked by the vast amounts of genome sequence data becoming available for many of the species in this diverse group. In this review, we summarize the current state of parasite genomics, provide details concerning the available drug andvaccine therapies for the diseases caused by these parasites, and describe the roles comparative genomics is playing in the design of new drugs and vaccines against them. These roles include the identification of various metabolic pathways or proteins that might serve as therapeutic targets by virtue of their presence in the parasite but absence in humans; elucidation of the causes of drug resistance and antibiotic sensitivity; identification of genes expressed in a stage-specific fashion; and detection of potential antigens for vaccine development. The future is bright for comparative genomic analysis of parasites, and the development of several public-private partnerships that foster collaborations among scientists in academia, big pharmaceutical companies, and the public sector provide new hope for the development of the next generation of antiparasitic therapeutics.

UR - http://www.scopus.com/inward/record.url?scp=85055466686&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055466686&partnerID=8YFLogxK

U2 - 10.1201/9781420008876

DO - 10.1201/9781420008876

M3 - Chapter

SN - 9780849392160

SP - 193

EP - 218

BT - Comparative Genomics

PB - CRC Press

ER -